Nanobodies News and Research

RSS

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

Scientists open new front against cause of sleeping sickness

Scientists of the Antwerp Institute of Tropical Medicine (ITG) opened a new front against the cause of sleeping sickness. This parasite is transmitted between humans by tsetse flies. The researchers learned a bacterium living in those flies how to produce antibodies against the parasite. Application in the field is still a long way of, but the technique shows quite some promise.

31 Aug 2012

Scientists image structure of bacterium protein coat

Bacteria are omnipresent - in the water, the air and the soil, as well as in plants, animals and even people. We tend to think of bacteria as pathogenic, causing disease. We associate them with intestinal upsets and throat infections, pneumonia and blood poisoning.

11 Jun 2012

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

In collaboration with a Brussels University team under the leadership of Nick Devoogdt and a French team from INSERM, Serge Muyldermans and his team, associated with VIB and Vrije Universiteit Brussel, have succeeded in developing the first patient-friendly, non-invasive method for differentiating dangerous strictures in blood vessels, so-called vulnerable atherosclerotic plaques, from less dangerous ones.

5 Apr 2012

Camel blood can help scientists fight against cancer

Nanobodies produced from camel blood have unique properties, which can be used in future drug development. New research published in Journal of Controlled Release confirms that camel blood can help scientists in the fight against cancer.

15 Jul 2011

Breast cancer patients can benefit from new nanobodies

A new discovery published online in The FASEB Journal promises to help physicians identify patients most likely to benefit from breast cancer drug therapies. If the compound, called "Nanobody," proves effective in clinical trials, it would represent a significant advance for breast cancer drug therapy because some drugs are effective only in some people.

12 Apr 2011

New strategy against Botulinum toxin

A study involving the world's deadliest substance has yielded a new strategy to clear toxins from the body-which may lead to more efficient strategies against toxins that may be used in a bioterrorist event, as well as snake bites, scorpion stings, and even some important chronic diseases.

26 Feb 2010

Merck Serono and Ablynx to jointly develop nanobodies

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has entered into an agreement with Ablynx, to co-discover and co-develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of EUR10 million.

4 Sep 2008

Domantis successful in patent opposition

Domantis Limited, the human Domain Antibody Therapeutics company, has successfully opposed European patent number EP0656946, leading to a major amendment of the main claim in the patent and a significant narrowing of the scope of 34 of the 41 other claims.

1 Sep 2005

Nanobodies herald a new era in cancer therapy

Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects.

12 May 2004